Drug lookup | Fillwise

Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): Teva-Trimel (00510637). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.

SULFAMETHOXAZOLE & TRIMETHOPRIM

Form:

9 of 9 products shown

3 general benefit · 6 not a benefit

Other products in the same Health Canada class (J01E) — coverage varies; not interchangeable

Trimethoprim (Proloprim): general benefit, Not a benefit

Sulfatrim · DIN 00445274 · 400mg & 80mg · tablet

General benefitMarketed · checked 2026-09-19

StatusGeneral benefit

Special Drugs ProgramSpecial Drugs Program: Amoxicillin, ascorbic acid (Vitamin C), deferoxamine, folic acid, hydrocortisone injection, penicillin and trimethoprim/sulfamethoxazole for the treatment of thalassaemia (ontario.ca, Updated 2023-07-13 ↗) Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗) The Special Drugs Program will cover costs for the above drugs if the patient: is an Ontario resident has a valid Ontario Health Insurance (OHIP) has one of the diseases or conditions covered meets the established clinical criteria is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Sulfatrim · DIN 00445274 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Daily cost (source): $0.8736 Health Canada: Marketed since 2019-06-07 · brand SULFATRIM · ATC J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM · form Tablet · route Oral · ingredients SULFAMETHOXAZOLE 400 MG, TRIMETHOPRIM 80 MG · company Aa pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Sulfatrim: Formulary list price $0.2184/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2184 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3678 · Verify on the e-Formulary ↗ (DIN 00445274)

Source record

DIN 00445274: Sulfatrim Raw flags: sec3=Y Item: 084000001; group id 139; item number 0233; lccId None; manufacturer id AAP Source form: Tab; strength: 400mg & 80mg Recorded listing: General benefit Source prices (unrounded): $0.2184; ministry $0.2184 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00445274 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3678

Interchangeable products

Bactrim · DIN 00272469 · not recorded Septra · DIN 00270636 · not recorded

Shortage status: resolved shortage (ended 2025-04-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00445274

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sulfatrim-DS · DIN 00445282 · 800mg & 160mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Sulfatrim-DS · DIN 00445282 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Daily cost (source): $0.4148 Health Canada: Marketed since 2019-04-10 · brand SULFATRIM DS · ATC J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM · form Tablet · route Oral · ingredients TRIMETHOPRIM 160 MG, SULFAMETHOXAZOLE 800 MG · company Aa pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Sulfatrim-DS: Formulary list price $0.2074/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2074 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 00445282: Sulfatrim-DS Raw flags: sec3=Y Item: 084000003; group id 139; item number 0234; lccId None; manufacturer id AAP Source form: Tab; strength: 800mg & 160mg Recorded listing: General benefit Source prices (unrounded): $0.2074; ministry $0.2074 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00445282 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3679

Interchangeable products

Bactrim-DS · DIN 00371823 · not recorded Septra DS · DIN 00368040 · not recorded

Shortage status: resolved shortage (ended 2025-04-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00445282

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Trimel · DIN 00726540 · 40mg & 8mg/mL · oral liquid

General benefitDormant since 2021-05-14 · checked 2026-09-02 · What does dormant mean?

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Teva-Trimel · DIN 00726540 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Daily cost (source): $1.0260 Health Canada: Dormant since 2021-05-14 · brand TEVA-TRIMEL · ATC J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM · form Suspension · route Oral · ingredients TRIMETHOPRIM 8 MG/ML, SULFAMETHOXAZOLE 40 MG/ML · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Teva-Trimel: Formulary list price $0.1026/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1026 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7313 · Verify on the e-Formulary ↗ (DIN 00726540)

Source record

DIN 00726540: Teva-Trimel Raw flags: sec3=Y Item: 084000002; group id 139; item number 0232; lccId None; manufacturer id TEV Source form: O/L; strength: 40mg & 8mg/mL Recorded listing: General benefit Source prices (unrounded): $0.1026; ministry $0.1026 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00726540 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7313

Interchangeable products

Bactrim Sugar Free · DIN 00272485 · not recorded Septra · DIN 00270644 · not recorded

Shortage status: active shortage (reported 2017-02-01, last updated 2017-10-13) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00726540

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Dormant since 2021-05-14 — choose a marketed DIN from the same-category list.

Bactrim Sugar Free · DIN 00272485 · 40mg & 8mg/mL · oral liquid

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-07-19 — choose a marketed DIN from the same-category list.Discontinued 2001-07-19 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-07-19 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2001-07-19 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Bactrim Sugar Free · DIN 00272485 Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01 Daily cost (source): $1.0260 Health Canada: Cancelled post market since 2001-07-19 · brand BACTRIM ROCHE SUSPENSION PAEDIATRIC · ATC J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM · form Suspension · route Oral · ingredients SULFAMETHOXAZOLE 200 MG/5ML, TRIMETHOPRIM 40 MG/5ML · company Hoffmann-la roche limited · schedule Prescription

Check this DIN again · Health Canada product record

Bactrim Sugar Free: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1721 · Verify on the e-Formulary ↗ (DIN 00272485)

Source record

DIN 00272485: Bactrim Sugar Free Raw flags: notABenefit=Y, sec3=Y Item: 084000002; group id 139; item number 0232; lccId None; manufacturer id HLR Source form: O/L; strength: 40mg & 8mg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00272485 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1721

Interchangeable products

Septra · DIN 00270644 · not recorded Teva-Trimel · DIN 00726540 · $0.1026

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00272485

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2001-07-19 — choose a marketed DIN from the same-category list.

Septra · DIN 00270644 · 40mg & 8mg/mL · oral liquid

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-10-07 — choose a marketed DIN from the same-category list.Discontinued 2025-10-07 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-10-07 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2025-10-07 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Septra · DIN 00270644 Manufacturer: Burroughs Wellcome Inc.; listing date 1996-10-01 Daily cost (source): $1.0260 Health Canada: Cancelled post market since 2025-10-07 · brand SEPTRA PEDIATRIC SUSPENSION · ATC J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM · form Suspension · route Oral · ingredients SULFAMETHOXAZOLE 40 MG/ML, TRIMETHOPRIM 8 MG/ML · company Aspen pharmacare canada inc. · schedule Prescription

Check this DIN again · Health Canada product record

Septra: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1705 · Verify on the e-Formulary ↗ (DIN 00270644)

Source record

DIN 00270644: Septra Raw flags: notABenefit=Y, sec3=Y Item: 084000002; group id 139; item number 0232; lccId None; manufacturer id BWE Source form: O/L; strength: 40mg & 8mg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00270644 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1705

Interchangeable products

Bactrim Sugar Free · DIN 00272485 · not recorded Teva-Trimel · DIN 00726540 · $0.1026

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2025-10-07 — choose a marketed DIN from the same-category list.

Bactrim · DIN 00272469 · 400mg & 80mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-07-27 — choose a marketed DIN from the same-category list.Discontinued 2000-07-27 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-07-27 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2000-07-27 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Bactrim · DIN 00272469 Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01 Daily cost (source): $0.8736 Health Canada: Cancelled post market since 2000-07-27 · brand BACTRIM ROCHE TAB · ATC J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM · form Tablet · route Oral · ingredients SULFAMETHOXAZOLE 400 MG, TRIMETHOPRIM 80 MG · company Hoffmann-la roche limited · schedule Prescription

Check this DIN again · Health Canada product record

Bactrim: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1804 · Verify on the e-Formulary ↗ (DIN 00272469)

Source record

DIN 00272469: Bactrim Raw flags: notABenefit=Y, sec3=Y Item: 084000001; group id 139; item number 0233; lccId None; manufacturer id HLR Source form: Tab; strength: 400mg & 80mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00272469 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1804

Interchangeable products

Septra · DIN 00270636 · not recorded Sulfatrim · DIN 00445274 · $0.2184

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2000-07-27 — choose a marketed DIN from the same-category list.

Septra · DIN 00270636 · 400mg & 80mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-07-31 — choose a marketed DIN from the same-category list.Discontinued 2003-07-31 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-07-31 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2003-07-31 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Septra · DIN 00270636 Manufacturer: Burroughs Wellcome Inc.; listing date 1996-10-01 Daily cost (source): $0.8736 Health Canada: Cancelled post market since 2003-07-31 · brand SEPTRA · ATC J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM · form Tablet · route Oral · ingredients TRIMETHOPRIM 80 MG, SULFAMETHOXAZOLE 400 MG · company Glaxosmithkline inc · schedule Prescription

Check this DIN again · Health Canada product record

Septra: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1704 · Verify on the e-Formulary ↗ (DIN 00270636)

Source record

DIN 00270636: Septra Raw flags: notABenefit=Y, sec3=Y Item: 084000001; group id 139; item number 0233; lccId None; manufacturer id BWE Source form: Tab; strength: 400mg & 80mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00270636 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1704

Interchangeable products

Bactrim · DIN 00272469 · not recorded Sulfatrim · DIN 00445274 · $0.2184

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2003-07-31 — choose a marketed DIN from the same-category list.

Bactrim-DS · DIN 00371823 · 800mg & 160mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-07-19 — choose a marketed DIN from the same-category list.Discontinued 2001-07-19 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-07-19 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Bactrim-DS · DIN 00371823 Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01 Daily cost (source): $0.4148 Health Canada: Cancelled post market since 2001-07-19 · brand BACTRIM DS ROCHE TAB · ATC J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM · form Tablet · route Oral · ingredients TRIMETHOPRIM 160 MG, SULFAMETHOXAZOLE 800 MG · company Hoffmann-la roche limited · schedule Prescription

Check this DIN again · Health Canada product record

Bactrim-DS: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2559 · Verify on the e-Formulary ↗ (DIN 00371823)

Source record

DIN 00371823: Bactrim-DS Raw flags: notABenefit=Y, sec3=Y Item: 084000003; group id 139; item number 0234; lccId None; manufacturer id HLR Source form: Tab; strength: 800mg & 160mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00371823 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2559

Interchangeable products

Septra DS · DIN 00368040 · not recorded Sulfatrim-DS · DIN 00445282 · $0.2074

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2001-07-19 — choose a marketed DIN from the same-category list.

Septra DS · DIN 00368040 · 800mg & 160mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-07-31 — choose a marketed DIN from the same-category list.Discontinued 2003-07-31 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-07-31 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Septra DS · DIN 00368040 Manufacturer: Burroughs Wellcome Inc.; listing date 1996-10-01 Daily cost (source): $0.4148 Health Canada: Cancelled post market since 2003-07-31 · brand SEPTRA DS TABLETS · ATC J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM · form Tablet · route Oral · ingredients TRIMETHOPRIM 160 MG, SULFAMETHOXAZOLE 800 MG · company Glaxosmithkline inc · schedule Prescription

Check this DIN again · Health Canada product record

Septra DS: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2521 · Verify on the e-Formulary ↗ (DIN 00368040)

Source record

DIN 00368040: Septra DS Raw flags: notABenefit=Y, sec3=Y Item: 084000003; group id 139; item number 0234; lccId None; manufacturer id BWE Source form: Tab; strength: 800mg & 160mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00368040 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2521

Interchangeable products

Bactrim-DS · DIN 00371823 · not recorded Sulfatrim-DS · DIN 00445282 · $0.2074

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2003-07-31 — choose a marketed DIN from the same-category list.

Other drugs in the same formulary class (08:40 Miscellaneous Anti-Infectives) and how they are covered

Matched class: 08:40 Miscellaneous Anti-Infectives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): CIPROFLOXACIN, LEVOFLOXACIN, MOXIFLOXACIN HYDROCHLORIDE, NORFLOXACIN, TRIMETHOPRIM 08:40 Miscellaneous Anti-Infectives

TRIMETHOPRIM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mg, 200mg · Tab

CIPROFLOXACIN

· 44 products · Limited Use, codes 533 (1), Listed, not a benefit (3), General benefit (40) · strengths: 10g/100mL, 250mg, 500mg, 750mg · Oral Susp, Tab

LEVOFLOXACIN

· 24 products · Listed, not a benefit (2), General benefit (14), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 250mg, 500mg, 750mg · Tab

MOXIFLOXACIN HYDROCHLORIDE

· 12 products · Listed, not a benefit (1), General benefit (11) · strengths: 400mg · Tab

NORFLOXACIN

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 400mg · Tab

CIPROFLOXACIN HCL & CIPROFLOXACIN BASE

· 2 products · Listed, not a benefit (1), Limited Use, codes 394 (1) · strengths: 500mg · ER Tab

LINEZOLID

· 6 products · Off-Formulary Interchangeable, not an ODB benefit (2), Listed, not a benefit (1), Limited Use, codes 362, 363, 364 (3) · strengths: 2mg/mL, 600mg · Inj-300mL Pk, Tab

CEFEPIME

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g, 2g · Inj Pd-Vial Pk

ERTAPENEM

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g/Vial · Inj Pd-Vial Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:40

Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:18 Antivirals, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.

What the Health Canada label says it is for

1. Indications SULFATRIM (sulfamethoxazole and trimethoprim tablets) is indicated for treatment of infections associated with the following gram-positive and gram-negative organisms: Gram-Negative Organisms Haemophilus influenzae Neisseria gonorrhoeae Escherichia coli Klebsiella species Enterobacter (Aerobacter) aerogenes Proteus mirabilis Proteus vulgaris Salmonella species Shigella species Vibrio cholerae Gram-Positive Organisms Streptococcus pyogenes Streptococcus viridans Staphylococcus albus Staphylococcus aureus Diplococcus pneumoniae Other Organisms Brucella melitensis Nocardia asteroides Nocardia brasiliensis Paracoccidioides brasiliensis Pneumocystis jiroveci Streptomyces somaliensis Sensitivity tests should be performed wherever possible to determine choice of therapy. These tests should be repeated if there is a failure to respond, relapse or early recurrence. SULFATRIM may be indicated for the following infections when caused by susceptible strains of the above organisms. Urinary Tract Infections: Treatment of acute uncomplicated urinary tract infections*. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single e… https://pdf.hres.ca/dpd_pm/00085471.PDF PM date: not printed or not captured Source product: SULFATRIM; DIN 00445274; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Teva-Trimel · DIN 00726540 Shortage status: active shortage (reported 2017-02-01, last updated 2017-10-13) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00726540

Check this DIN again

Health Canada: dormant products

Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Bactrim Sugar Free, Septra, Bactrim, Bactrim-DS, Septra DS: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote

Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote

Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026